Comparing treatments for cutaneous leishmaniasis
Treatments studied
Part of Infections, Skin clinical trials.
This study tests different drugs to find which works best for cutaneous leishmaniasis (a skin infection from a parasite). It may help people with many or large sores, or sores in sensitive areas like near the eyes or nose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of cutaneous leishmaniasis (a skin infection from a parasite).
- You are between 4 and 65 years old.
- You need treatment for the whole body because your sores are too many (more than 4), too large (more than 4 cm), near your nose or eyes, or have not healed with other treatments.
- You agree to stay in the hospital during treatment and to come back for follow-up visits.
- If you are a woman who could become pregnant, you must use birth control during treatment and for 5 months after, but only if you get the drug miltefosine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well miltefosine works for people with leishmaniasis, a skin infection from a parasite. It aims to find the best way to use this medicine to help patients get better.
This study tests if using heat therapy (thermotherapy) in local clinics is a good way to treat skin sores caused by leishmaniasis. It may be an option for people with a few small sores not on the face or near sensitive areas.
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
This trial tests if oral medicines can treat cutaneous (skin) or mucosal leishmaniasis in people aged 60 and older. It compares two different pills to find a safer, easier option for elderly patients.
This study tests two new oral medicines compared to an existing oral medicine for people with a first episode of cutaneous leishmaniasis (skin sores caused by a parasite). It aims to find a more effective and convenient treatment.
This study tests a gel form of miltefosine applied directly to skin sores caused by leishmaniasis. It is for adults with mild to moderate skin infections who have not already tried and failed other treatments.
Hear when a new Cutaneous Leihmaniasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.